2Sartorius N,Baghai TC,Baldwin DS,et al.Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence[J]. Int J Neuropsychopharmacol,2007,10 (Suppl.1): S1-207.
3Millan MJ.Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates,drug discovery and therapeutic application[J]. Pharmacol THer,2006,110(2): 135-370.
4Souêtre E,Salvati E,Belugou JL,et al.Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality[J]. Psychiatry Res,1989,28(3): 263-278.
5Duncan WC Jr.Circadian rhythms and the pharmacology of affective illness[J]. Pharmacol Ther,1996,71(3): 253-312.
6Germain A,Kupfer DJ.Circadian rhythm disturbances in depression[J]. Hum Psychopharmacol,2008,23(7): 571-585.
7Audinot V,Mailliet F,Lahaye-Brasseur C,et al.New selective ligands of human cloned melatonin MT1 and MT2 receptors[J]. Naunyn Schmiedebergs Arch Pharmacol,2003,367(6): 553-561.
8Kasper S,Hamon M.Beyond the monoaminergic hypothesis: agomelatine,a new antidepressant with an innovative mechanism of action[J]. World J Biol Psychiatry,2009,10(2): 117-126.
9de Bodinat C,Guardiola-Lemaitre B,Moca r E,et al.Agomelatine,the first melatonergic antidepressant: discovery,characterization and development[J]. Nat Rev Drug Discov,2010,9(8): 628-642.
10Yous S,Andrieux J,Howell HE,et al.Novel naphthalenic ligands with high affinity for the melatonin receptor[J]. J Med Chem,1992,35(8): 1484-1486.
